TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03318666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supporting Our Valued Adolescents (SOVA)
Description: The SOVA intervention includes:~* a welcome email to the websites (adolescents also get a SOVA intro video and mobile app)~* adolescents will have access to the website specifically for adolescents: sova.pitt.edu~* parents will have access to the website specifically for parents: wisesova.pitt.edu~These anonymous websites aim to: (1) challenge negative health beliefs and increase depression/anxiety knowledge through daily blog posts enhanced with peer commentary; (2) promote social support through online peer interactions; and (3) encourage parent-adolescent mental health communication through same day blog posts with questions for discussion. Parents and adolescents cannot log on to each other's sites. The sites are moderated by our research team.~The SOVA websites include articles composed by SOVA Peer Ambassadors who are adolescents and young adults who have experienced symptoms of depression or anxiety and contribute monthly articles and regular comments.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: A social worker at the Center for Adolescent and Young Adult Health (CAYAH) clinic helps to facilitate referrals from the adolescent healthcare provider (AHCP) and contacts patients who do not schedule for within-CAYAH appointments.The study will send an extra email to the parent and adolescent that contains the content of the depart summary as well as a list of psychoeducational materials, how to contact the AHCP, CAYAH social worker, and crisis resources and the AHCP's treatment recommendation which are obtained from the electronic health record. Also, each individual will receive a phone call from a research assistant who will communicate the information in the email and offer to inform the social worker or AHCP of questions the patient or parent may have.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care
Description: A social worker at the Center for Adolescent and Young Adult Health (CAYAH) clinic helps to facilitate referrals from the adolescent healthcare provider (AHCP) and contacts patients who do not schedule for within-CAYAH appointments.The study will send an extra email to the parent and adolescent that contains the content of the depart summary as well as a list of psychoeducational materials, how to contact the AHCP, CAYAH social worker, and crisis resources and the AHCP's treatment recommendation which are obtained from the electronic health record. Also, each individual will receive a phone call from a research assistant who will communicate the information in the email and offer to inform the social worker or AHCP of questions the patient or parent may have.
Study: NCT03755388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Episealer
Description: Placing Episealer device
Study: NCT00816114

Intervention type: OTHER
Intervention: Chart Review
Description: Investigator review of MDACC CML patient charts.
Study: NCT00976677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study: NCT04552925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Exercises and rehabilitation for massive rotator cuff tears

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Exercises and rehabilitation for massive rotator cuff tears
Study: NCT03950791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Catastrophizing Class
Description: A 2-hour class that will be delivered by a clinical psychologist to participant cohorts. Didactic content includes psychoeducation about opioid use, the risk for misuse, and opioid reduction education materials. It will also include mind-body science as it relates to pain and PC. Participants learn how to identify catastrophizing in the moment, and how to self-treat it. During the class, participants acquire skills and develop a plan to apply the learned skills to decrease physiological hyperarousal within the context of PC. Participants also acquire skills that improve the regulation of cognition and emotion, including PC reframing and thought restructuring, and develop a plan for implementing these skills in daily life. Finally, participants develop a plan to use behaviors that modulate attention and counteract helplessness.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education
Description: Education about improving lifestyle factors to improve participants' overall health.
Study: NCT03747419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab is a form of immunotherapy, which means it is designed to help the patient's immune system kill cancer cells.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Cancer treatment that uses ionizing radiation to kill cancer cells.
Study: NCT01067521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Description: GA 40 mg/mL administered 3 times a week by subcutaneous injection for a period of 12 months for participants assigned to GA treatment in the Double-Blind Period, and GA 40 mg/mL administered 3 times a week by subcutaneous injection for all participants in the Open-Label Extension Period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glatiramer acetate (GA)
Description: GA 40 mg/mL administered 3 times a week by subcutaneous injection for a period of 12 months for participants assigned to GA treatment in the Double-Blind Period, and GA 40 mg/mL administered 3 times a week by subcutaneous injection for all participants in the Open-Label Extension Period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator administered by subcutaneous injection three times each week for 12 months during the Double-Blind Period.
Study: NCT04278924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-079
Description: TAK-079 SC injection.
Study: NCT03405064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Levonadifloxacin/Linezolid Tablet
Description: oral levonadifloxacin (1000 mg BID) or oral linezolid (600 mg BID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Levonadifloxacin/Linezolid Tablet
Description: oral levonadifloxacin (1000 mg BID) or oral linezolid (600 mg BID)
Study: NCT05821894

Intervention type: OTHER
Intervention: Observational study
Study: NCT03290079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Pembrolizumab by IV on Day 1 of each 3 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20 mg Lenvatinib by mouth every day of each 3 week cycle
Study: NCT03605927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986004
Description: BMS-986004 will be administered in ascending dose cohorts in the phase I component of the trial. Based on prior PK and PD data, dose levels of 225 mg, 675 mg, and 1500 mg (3 total phase I dose levels) will be examined. BMS-986004 will be given intravenously (IV) every 2 weeks, starting from day -3 (i.e., three days prior to HCT) onward through a total of 100 days post-HCT. The maximum tolerated dose (MTD) identified in the phase I component of the trial will be carried forward as the recommended dose level in the phase 1 expansion cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus and tacrolimus (standard of care pharmacologic immune suppression) will be given according to institutional standards.~Sirolimus (SIR) will be given as a loading dose on day -1 orally, then daily as maintenance therapy with target levels of 10-14ng/mL early post-HCT, then tapered to 5-14ng/mL range.~Program standards will be used for SIR and TAC level monitoring frequency and dose adjustments, including careful attention to drug-interactions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Sirolimus and tacrolimus (standard of care pharmacologic immune suppression) will be given according to institutional standards.~In brief, tacrolimus (TAC) will be started on day -3 IV, and transitioned to oral TAC when oral medications are tolerated; target level is 3-7ng/mL.~Program standards will be used for SIR and TAC level monitoring frequency and dose adjustments, including careful attention to drug-interactions.
Study: NCT03802227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-181
Description: A combination of NKTR-181 and oxycodone IR placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone IR
Description: A combination of oxycodone IR and NKTR-181 placebo
Study: NCT04676854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRIMA Bionic Vision System
Description: Implantation of PRIMA, Vision training, follow up
Study: NCT03405064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Levonadifloxacin/Linezolid Infusion
Description: IV levonadifloxacin (800 mg BID) or IV linezolid (600 mg BID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Levonadifloxacin/Linezolid Infusion
Description: IV levonadifloxacin (800 mg BID) or IV linezolid (600 mg BID)
Study: NCT04566549

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Test group Probiotic Shampoo
Description: Probiotic Shampoo

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Shampoo base
Study: NCT02077335

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR brachytherapy monotherapy
Description: Radiation therapy in the study consists of treatment with 2 separate interstitial HDR brachytherapy procedures with temporary interstitial catheters, each with one fraction of 13.5 Gray (Gy). Both procedures will be done in an identical manner. The 2 procedures will be separated by an interval of 7-14 days Treatments will be done with interstitial catheters inserted transperineally with transrectal ultrasound guidance under sterile conditions. Optimization of treatment plan will be done with Brachyvision software (Varian, Palo Alto CA) based on CT-scan imaging done post-implant. Optimization parameters will be the following:~Prostate :~* V100 \> 95%~* V150 30-35%~* V200 \< 15%~* D90 \> 90% (12,15Gy)~Bladder~• V75 \< 1cc~Rectum~• V75 \< 1cc~Urethra~V125 = 0cc D10 \< 120%~Treatments will be carried out with an Iridium-192 afterloader. Source and all catheters will be removed from the patient at the end of the procedure.
Study: NCT04060849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nozin
Description: Given via nasal single-use popswabs or single-use cotton tipped applicators

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care
Study: NCT02603328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 40-80 mg OD

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive
Study: NCT06680505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-1139 10mg
Description: YZJ-1139 10mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-1139 20mg
Description: YZJ-1139 20mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-1139 40mg
Description: YZJ-1139 40mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-1139 60mg
Description: YZJ-1139 60mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Match placebo tablets
Study: NCT04472468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Balloon Pericardiotomy
Description: * Subxiphoid approach under fluoroscopic guidance is used.~* An 20mm over-the-wire ultra-non-compliant Percutaneous Transluminal Angioplasty Balloon is advanced into the pericardial space.~* Success of balloon pericardiotomy is confirmed by full inflation of the balloon which is confirmed on two orthogonal projections.
Study: NCT02176616

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: linear ablation
Description: The group of positive control is the operation to add in conventional liner ablation to conventional pulmonary vein isolation with in patients based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulmonary vein isolation
Description: The group of negative is the operation to patients with only pulmonary vein isolation based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
Study: NCT03274336

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: movie
Description: after seeing a film about the procedure a face-to-face interview will take place

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: movie
Description: after seeing a film about the procedure a face-to-face interview will take place
Study: NCT01106534

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo + aspirin
Description: This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel + aspirin OR prasugrel + aspirin
Description: This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive an additional 18 months of thienopyridine (clopidogrel or prasugrel) treatment in addition to aspirin.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)
Description: XIENCE V Everolimus Eluting Coronary Stent System assigned to both the arms.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)
Description: XIENCE V Everolimus Eluting Coronary Stent System assigned to both the arms.
Study: NCT02929992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ART initiation in the home
Description: Participants initiate ART use in the home without visiting a clinic

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Van Refill and Monitoring
Description: Participants will pick up their medication refills from the mobile van and have all clinical monitoring conducted in the mobile van.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Van Refill and Monitoring
Description: Participants will pick up their medication refills from the mobile van and have all clinical monitoring conducted in the mobile van.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinic ART Initiation
Description: Participants are referred to the clinic to initiate ART use

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinic ART Initiation
Description: Participants are referred to the clinic to initiate ART use

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinic ART Refill and Monitoring
Description: Participants will return to the clinic for ART refill and clinical monitoring.
Study: NCT04207853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body vibration em DM
Description: The vibrating platform is a new biophysical modality of exercise. The individual exercises on a plate that oscillates up and down movements at a specific frequency and amplitude, and the exercises are performed static and / or dynamic. Vibration is supposed to activate muscle spindles and evoke contractions, which are induced by the complex spinal and supraspinal neurophysiological mechanism known as the tonic vibration reflex.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Vibration sham em DM
Description: Sham vibration will be performed with the platform disconnected. A sound device will be connected producing a noise similar to the connected platform for a time equivalent to the treatment protocol, as it will not be possible to visibly distinguish the vibratory stimulus. Participants who will undergo false vibration will not have contact with those who will perform the protocol effectively.
Study: NCT04207853

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: whole body vibration em NDM
Description: The vibrating platform is a new biophysical modality of exercise. The individual exercises on a plate that oscillates up and down movements at a specific frequency and amplitude, and the exercises are performed static and / or dynamic. Vibration is supposed to activate muscle spindles and evoke contractions, which are induced by the complex spinal and supraspinal neurophysiological mechanism known as the tonic vibration reflex.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Vibration sham em NDM
Description: Sham vibration will be performed with the platform disconnected. A sound device will be connected producing a noise similar to the connected platform for a time equivalent to the treatment protocol, as it will not be possible to visibly distinguish the vibratory stimulus. Participants who will undergo false vibration will not have contact with those who will perform the protocol effectively.
Study: NCT01680406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine combination
Study: NCT03676790

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group V
Description: Group V Patients received only exercise sessions three times a week for two months.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius).
Study: NCT00730652

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDX-1411
Description: Single dose of MDX-1411 (fully human monoclonal antibody) will be administered as an intravenous (i.v.) infusion every 7 days for up to a total of 5 doses.
Study: NCT00762411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY450139
Description: Administered orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally once daily.
Study: NCT03508154

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Meal 1
Description: carbohydrate test meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Meal 2
Description: carbohydrate test meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Nutritional Product
Description: ready to drink nutritional formulation
Study: NCT02682108

Intervention type: DEVICE
Group type: OTHER
Intervention: Diffusion-weighted magnetic resonance imaging (DW-MRI)
Description: Magnetic resonance (MR) imaging examination of liver will be performed on a 3.0T Achieva MR scanner (Philips Medical Systems, The Netherlands). Diffusion-weighted imaging (DWI) will be performed using a single-shot echo-planar imaging during a single end expiratory breath-hold. A single observer placed circular regions of interest around 2.30 cm2 to measure mean signal intensity (SI) in the right hepatic lobe and the spleen for each b value, avoiding areas of artifact, vessels, and focal lesions. A monoexponential fit will be performed to calculate liver and spleen apparent diffusion coefficient (ADC) on the basis of ln(SI) as a function of b value, using all b values. Normalized liver ADC will be calculated as the ratio of liver ADC to spleen ADC.
Study: NCT02979041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive virtual reality training
Description: The proposed VR intervention program will provide active training to be performed individually 4 times a week for 20 minutes a session.~The intervention program will be supervised by qualified, experienced physiotherapists, and will include individual training and two follow up meetings during the study period. The intervention program will include strengthening and endurance exercises for the cervical and shoulder girdle muscles. Training will include sensorimotor control and functional, quick, accurate, neck motion, using interactive VR training systems. This type of advanced training is very relevant to the pilots function in the cockpit as it includes interactive tasks aimed to increase range, speed, smoothness, accuracy, and control of cervical motion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: physiotherapy and medical care as provided currently
Study: NCT03028155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin: BSA-based HIPEC
Description: oxaliplatin: 460 mg/m2 volume: dependent on the capacity of the peritoneal cavity of the patient

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin: Concentration-based HIPEC
Description: oxaliplatin: 230 mg/L
Study: NCT00337558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Description: tablet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simplified bladder training
Description: Instructions
Study: NCT01652508

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants in the control group are provided a self-help leaflet on smoking cessation only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: All participants are given an initial smoking cessation session via face to face by Acceptance and Commitment Therapy. Two other sessions using the same therapy will be provided by telephone. The total contact time by ACT will be 45 mins (15 mins per session).
Study: NCT05253430

Intervention type: PROCEDURE
Intervention: Lymphadenectomy type
Description: D1 vs D2 lymph node dissection
Study: NCT02784496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long-term Follow-up
Description: Undergo follow-up assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies